Respiratory Syncytial Virus Infections: all 302 studies

Page 1 of 4. Open to participants first (48), then studies with results posted, then the rest; newest registration first within each.

• Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France RegionNot yet recruitingNCT07882186
• Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.Not yet recruitingNCT07881991Phase 2
• The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration EvaluationNot yet recruitingNCT07824167Phase 4
• Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant BronchiolitisNot yet recruitingNCT07778225
• A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.RecruitingNCT07658534Phase 2/3
• Expression of Inflammatory Markers in the Course of Acute Respiratory Viral InfectionsNot yet recruitingNCT07643688
• Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan FranceRecruitingNCT07599449
• Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.RecruitingNCT07582796Phase 1/2
• Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgeRecruitingNCT07516418Phase 1
• Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University HospitalNot yet recruitingNCT07505420
• A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusRecruitingNCT07482657Phase 2
• Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese InfantsNot yet recruitingNCT07417657
• A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young ChildrenRecruitingNCT07402512Phase 3
• RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSVNot yet recruitingNCT07346963
• Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )RecruitingNCT07239583
• Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNot yet recruitingNCT07235397
• A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseRecruitingNCT07214571Phase 2
• A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.RecruitingNCT06955728Phase 3
• Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in FranceRecruitingNCT06881953
• Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSVRecruitingNCT06873633Phase 2
• A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseRecruitingNCT06866405Phase 3
• Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.RecruitingNCT06856967
• Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy AdultsRecruitingNCT06843317Phase 1
• Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsRecruitingNCT06817889Phase 2
• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)RecruitingNCT06684379Phase 1/2
• RSV Vaccination in Immunocompromised Patients.RecruitingNCT06597916Phase 2
• An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)RecruitingNCT06490549
• Age Related Differences in Respiratory Immune Responses in Influenza Virus InfectionEnrolling by invitationNCT06401720
• Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract InfectionsRecruitingNCT06363370Phase 3
• A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy AdultsNot yet recruitingNCT06344975Phase 1/2
• Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The NetherlandsRecruitingNCT06318936
• A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy AdultRecruitingNCT06313697Phase 1
• A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy AdultsNot yet recruitingNCT06287450Phase 1
• Prevalence and Impact of Pertussis and RSV on Asthma Severity and ControlRecruitingNCT06286007
• Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.RecruitingNCT06259487Not applicable
• Evaluation of Lung Ultrasonography Findings in Newborns With Respiratory Syncytial Virus BronchiolitisEnrolling by invitationNCT06204367
• Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSVRecruitingNCT06197152
• Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine ImmunizationRecruitingNCT06180993
• Real-World Effectiveness of Perinatal RSV ImmunoprophylaxisRecruitingNCT06172660
• FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation ProtocolNot yet recruitingNCT05928507
• Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, WuhanEnrolling by invitationNCT05767294
• A Study of BLB-201 RSV Vaccine in Infants and ChildrenRecruitingNCT05655182Phase 1/2
• Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm InfantsRecruitingNCT05618769Not applicable
• Impact of the Covid-19 on RSV Epidemic in the Metropolis of LyonNot yet recruitingNCT05348655
• Impact of the Covid-19 on RSVNot yet recruitingNCT05348616
• Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenRecruitingNCT05026749Phase 3
• Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial VirusNot yet recruitingNCT05017519
• RSV Burden in Outpatient and Hospital SettingsRecruitingNCT04743609Not applicable
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT06784973Phase 2Results posted
• A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)CompletedNCT06614725Phase 3Results posted
• Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT06585150Phase 2Results posted
• A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and OlderCompletedNCT06551181Phase 3Results posted
• A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.CompletedNCT06473519Phase 3Results posted
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and AboveCompletedNCT06389487Phase 3Results posted
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and AboveCompletedNCT06374394Phase 3Results posted
• A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelCompletedNCT06170242Phase 2Results posted
• A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSVTerminatedNCT06102174Phase 1Results posted
• A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT06079320Phase 2/3Results posted
• A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of NirsevimabCompletedNCT06042049Phase 3Results posted
• A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.CompletedNCT05987072Phase 1Results posted
• A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsCompletedNCT05966090Phase 3Results posted
• A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and AboveCompletedNCT05921903Phase 2Results posted
• Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older AdultsCompletedNCT05879107Phase 3Results posted
• A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/ControlCompletedNCT05705440Phase 3Results posted
• Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)CompletedNCT05687279Phase 1/2Results posted
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and AboveCompletedNCT05590403Phase 3Results posted
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedNCT05568797Phase 3Results posted
• A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.CompletedNCT05568706Phase 2Results posted
• A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedNCT05559476Phase 3Results posted
• MVA-BN-RSV Vaccine TrialTerminatedNCT05238025Phase 3Results posted
• A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of AgeCompletedNCT05169905Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy AdultsCompletedNCT05118386Phase 1Results posted
• A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV InfectionCompletedNCT05070546Phase 3Results posted
• A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and AboveCompletedNCT05059301Phase 3Results posted
• A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.CompletedNCT05045144Phase 3Results posted
• A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated MothersTerminatedNCT04980391Phase 3Results posted
• Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)CompletedNCT04938830Phase 3Results posted
• Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveCompletedNCT04886596Phase 3Results posted
• A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and AboveCompletedNCT04841577Phase 3Results posted
• Study of RSVpreF Vaccination and RSV Challenge in Healthy AdultsCompletedNCT04785612Phase 2Results posted
• Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)CompletedNCT04767373Phase 2/3Results posted
• Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveActive, not recruitingNCT04732871Phase 3Results posted
• Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 StudyCompletedNCT04657198Phase 2Results posted
• Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractTerminatedNCT04633187Phase 2Results posted
• A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated MothersTerminatedNCT04605159Phase 3Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT04520659Phase 1Results posted
• Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersCompletedNCT04491877Phase 1/2Results posted
• Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised ChildrenCompletedNCT04484935Phase 2Results posted
• Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory PathogensTerminatedNCT04431050Results posted
• A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant WomenCompletedNCT04138056Phase 2Results posted
• Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their InfantsCompletedNCT04126213Phase 2Results posted
• A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older AdultsCompletedNCT04090658Phase 1Results posted
• Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)TerminatedNCT04056611Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)CompletedNCT03979313Phase 3Results posted
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk ChildrenCompletedNCT03959488Phase 2/3Results posted
• A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older AdultsCompletedNCT03814590Phase 1/2Results posted
• The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial VirusCompletedNCT03728413Not applicableResults posted
• A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelCompletedNCT03691623Phase 2Results posted
• A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant WomenCompletedNCT03674177Phase 1Results posted
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionTerminatedNCT03656510Phase 2Results posted

← Respiratory Syncytial Virus Infections overview